FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib

(MedPage Today) -- The FDA has withdrawn approval of the PI3K inhibitor umbralisib (Ukoniq) for marginal zone lymphoma (MZL) and follicular lymphoma because of safety concerns, the agency announced in a safety communication.
The action follows...